YM 022

a potent and selective gastrin/cholecystokinin-B receptor antagonist; structure given in first source

Also Known As:

1-(2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-(3-methylphenyl)urea; YM-022; YM022; Urea, N-(2,3-dihydro-1-(2-(2-methylphenyl)-2-oxoethyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3-methylphenyl)-, (R)-

Networked: 16 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzazepines: 5
      - Benzodiazepines: 8452
        YM 022: 16

Experts

1.	Fekete, Kata: 1 article (01/2022)
2.	Furedi, Nora: 1 article (01/2022)
3.	Garami, Andras: 1 article (01/2022)
4.	Gaszner, Balazs: 1 article (01/2022)
5.	Kelava, Leonardo: 1 article (01/2022)
6.	Keringer, Patrik: 1 article (01/2022)
7.	Miko, Alexandra: 1 article (01/2022)
8.	Olah, Emoke: 1 article (01/2022)
9.	Pakai, Eszter: 1 article (01/2022)
10.	Romanovsky, Andrej A: 1 article (01/2022)

Related Diseases

1.	Hyperalgesia 12/29/1995 - "In the 5 week study, but not the 1 week study, YM022 attenuated the level of thermal hyperalgesia in a dose-dependent manner. " 12/15/2021 - "The CCK2 receptor antagonist YM-022 significantly reduced the expression of p-ERK1/2. These data indicate that upregulation of CCK2 receptors through the MAPK pathway contributes to somatic hyperalgesia in this comorbid pain model. " 12/29/1995 - "To gain a better understanding of the role of cholecystokinin (CCK)-B receptor in the maintenance of thermal hyperalgesia induced by unilateral constriction injury to the sciatic nerve in the rat, this study evaluated the effects of intrathecally administered YM022 (a CCK-B receptor antagonist) on thermal hyperalgesia. " 05/01/2011 - "Pre-treatment with lidocaine, lorglumide or YM022 did not prevent the development of secondary allodynia or hyperalgesia regardless of the administration route. " 06/01/2011 - "RVM microinjection of lidocaine, kynurenic acid (excitatory amino acid antagonist) or YM022 (CCK2 receptor antagonist) blocked withdrawal-induced hyperalgesia. "
2.	Inflammation (Inflammations) 07/01/1996 - "To gain a better understanding of the roles of CCK-A and CCK-B receptors in spinal nociceptive transmission during inflammation, this study evaluated the effects of intrathecally administered FK480 (a CCK-A receptor antagonist) and YM022 (a CCK-B receptor antagonist). " 12/15/2021 - "Intrathecal injection of the CCK2 receptor antagonist YM-022 or mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitor PD98059 blocked somatic hyperalgesia induced by orofacial inflammation combined with stress. "
3.	Gastric Fistula 01/01/1998 - "In the gastric fistula cat, i.v. administration of YM022 produced a similar inhibitory effect with an ID50 of 0.02 mumol/kg in comparison to 1.6 and 2.5 mumol/kg for CI-988 and L-365,260, respectively. " 04/01/1998 - "The selective cholecystokinin-B/gastrin receptor antagonist YM022 (3 mumol.kg-1.hr-1) was given to gastric fistula rats by continuous subcutaneous infusion via osmotic minipumps for various times from 2 hr to 4 weeks. " 12/01/1996 - "Gastrin, histamine, insulin or bethanechol were administered to conscious gastric fistula rats with or without the concomitant intravenous infusion of YM022 or RP73870. "
4.	Neoplasms (Cancer) 01/01/2018 - "YM022 and Y-27632 significantly suppressed hepatic metastasis of orthotic pancreatic tumors induced by gastrin in vivo. " 07/01/1996 - "In the absence of exogenous peptide ligands, YM022 also inhibited the proliferation of several human cancer cell lines expressing the genes for both gastrin and its receptor. "
5.	Neuroendocrine Carcinoma 01/01/2017 - "The direct effect of gastrin and the gastrin receptor antagonist YM022 on expression and phosphorylation of the cyclin inhibitor p27Kip1 was tested on the human human gastric adenocarcinoma cell line stably expressing CCKBR (AGSE) and mouse small intestinal neuroendocrine carcinoma (STC)-1 cell lines. "

Related Drugs and Biologics

1.	Cholecystokinin B Receptor
2.	Cholecystokinin (Pancreozymin)
3.	Cholecystokinin A Receptor
4.	FR 120480
5.	Gastrins
6.	Famotidine (Pepcid)
7.	Lidocaine (Xylocaine)
8.	Histamine (Histamine Dihydrochloride)
9.	5-HT2B Serotonin Receptor
10.	Mitogen-Activated Protein Kinase Kinases (MEKs)

Related Therapies and Procedures

1.	Spinal Injections
2.	Subcutaneous Infusions
3.	Intravenous Infusions